2019 American Society of Clinical Oncology Annual Meeting*

Download All
May 31 - June 4, 2019; Chicago, Illinois
Review slidesets and analyses of key data from the 2019 Oncology meeting.

Gynecological Cancer

Capsule Summary Slidesets

In patients with recurrent ovarian cancer, the chemotherapy-free combination of niraparib plus bevacizumab significantly improved PFS vs niraparib alone, regardless of HRD status or chemotherapy-free interval.

Released: June 7, 2019

Olaparib treatment was associated with significant improvements in ORR and PFS vs nonplatinum chemotherapy for patients with platinum-sensitive relapsed ovarian cancer and germline BRCA mutation.

Released: June 11, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue